63rd ASH Annual Meeting and Exposition: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis

Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis (ASH 2021)

Read the full article here

Source: ash.confex.com

Categories: Latest Headlines

Tweets with this article

Eric Raible

Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis (ASH 2021)

Paper: Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma: Clinic al and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services…

Al-Ola A Abdallah MD April 18, 2024

Webprogram Unavailable

Please click HERE if you are not redirected in 5

Mike Thompson, MD, PhD, FASCO April 18, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…

Mike Thompson, MD, PhD, FASCO April 12, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO April 9, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO April 6, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 21, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 13, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 11, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 7, 2024

Paper: Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia – Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Program: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for…

Faheema Hasan MD 👩‍⚕️ March 3, 2024

Related Articles